Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

Necrolytic Migratory Erythema The 'glucagonoma syndrome' is characterised by necrolytic migratory erythema, diabetes and diarrhoea. Response of glucagonomas to surgical excision and chemotherapy. The glucagonoma syndrome is characterized by elevated serum glucagon, a pancreatic alpha-cell tumor, anemia, hypoaminoacidemia, and necrolytic migratory erythema. www.thedoctorsdoctor.com /diseases/nem.htm   (4775 words)

Glucagonoma -- Facts, Info, and Encyclopedia article   (Site not responding. Last check: 2007-10-08) Diabetes mellitus is present in 80-90% of cases of glucagonoma, and is exacerbated by preexisting (additional info and facts about insulin resistance) insulin resistance. A CBC can uncover anemia, which is an abnormally low level of (A hemoprotein composed of globin and heme that gives red blood cells their characteristic color; function primarily to transport oxygen from the lungs to the body tissues) hemoglobin. The only curative therapy for glucagonoma is (additional info and facts about surgical) surgical resection, where the tumor is removed. www.absoluteastronomy.com /encyclopedia/g/gl/glucagonoma.htm   (338 words)

Endotext.com - Glucagonoma Syndrome Several metabolic disorders are associated with cutaneous lesions closely resembling the NME of the glucagonoma syndrome. Glucagonomas not associated with the syndrome but characterized by morphologic and/or chemical criteria are diagnosed in various ways. Glucagonoma also may occur as a single microadenoma found incidentally at autopsy in elderly patients (317). www.endotext.org /guthormones/guthormone7/guthormone7.htm   (1058 words)

Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased "large glucagon-immunoreactivity".   (Site not responding. Last check: 2007-10-08) Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased "large glucagon-immunoreactivity".However, relative to immunoreactivity, peak II showed reduced activity (25--33%). The percent of IRG associated with peak II was 9.5--31.5% in normals and 39.1--61.2% in glucagonomas. Glucagonoma patients differed from our normal and reported normal subjects in that peak II contained most of the circulating IRG. www.pdg.cnb.uam.es /UniPub/iHOP/gp/2632938.html   (216 words)

Introduction: Glucagonoma - WrongDiagnosis.com Glucagonoma: Glucagonoma is a rare type of endocrine pancreatic tumor. Researching symptoms of Glucagonoma: Further information about the symptoms of Glucagonoma is available including a list of symptoms of Glucagonoma, other diseases that might have similar symptoms in differential diagnosis of Glucagonoma, or alternatively return to research other symptoms in the symptom center. Statistics and Glucagonoma: Various sources and calculations are available in statistics about Glucagonoma, prevalence and incidence statistics for Glucagonoma, and you can also research other medical statistics in our statistics center. www.wrongdiagnosis.com /g/glucagonoma/intro.htm   (319 words)

Glucagonoma Glucagonoma is a tumor of the islet cells of the pancreas, which secrete the hormones insulin and glucagon. Glucagonoma is usually malignant, which means that it has a tendency to spread and get worse. The islet cells of the pancreas are affected by this cancer, and as a result, they produce too much of a hormone called glucagon. www.hmh.net /adam/encyclopedia/hhe%20articles/000326.htm   (203 words)

* Glucagon - (Disease): Definition   (Site not responding. Last check: 2007-10-08) Glucagonoma is a of the islet cells of the pancreas, which secrete the hormones insulin and. A hormone produced by the pancreas that increases the level of glucose (sugar) in the blood. Symptoms of glucagonoma include a distinctive skin rash, inflammation of the stomach, glucose intolerance,... www.bestknows.com /disease/glucagon.html   (490 words)

Endocrine Surgeon A glucagonoma is a very rare pancreatic islet cell tumour secreting excessive amounts of glucagon. This accounts for some of the symptoms observed in the glucagonoma syndrome, but the majority remain unexplained. The estimated prevalence of glucagonoma is 1 in 20, 000, 000 people. www.endocrinesurgeon.co.uk /pancreas/pancreas6.html   (147 words)

Necrolytic migratory erythema (glucagonoma syndrome). DermNet NZ Necrolytic migratory erythema is a characteristic rash usually occurring in the glucagonoma syndrome. Glucagonoma syndrome is due to a slow-growing cancerous tumour located in the alpha cells of the pancreas. A glucagonoma is usually detected in the tail of the pancreas by computed tomography (CT scan), although conventional chest x-ray, magnetic resonance imaging (MRI) and coeliac axis angiography may also be useful. www.dermnetnz.org /systemic/necrolytic-erythema.html   (471 words)

Echenique-Elizondo M, et al. Glucagonoma and Pseudoglucagonoma Syndrome. JOP. J Pancreas (Online) 2004; 5(4):179-185. ... From January 1998 to December 2003, 5 cases were treated for glucagonoma syndrome: 3 with a demonstrable pancreatic neoplasm (true glucagonoma syndrome) and 2 cases without a pancreatic neoplasm (pseudoglucagonoma syndrome). Glucagonoma syndrome is a paraneoplastic phenomenon characterized by the existence of a glucagons-secreting neoplasm associated with hyperglucagonemia, NME, diabetes mellitus, hypo-aminoacidemia, cheilitis, normocytic anemia, vein thrombosis, loss of weight and neuropsychiatric manifestations [2]. Glucagonomas are slow-growing neoplasms with non-specific symptoms at the beginning. www.joplink.net /prev/200407/04.html   (2300 words)

eMedicine - Glucagonoma Syndrome : Article by Nathalie C Zeitouni, MD, CM, FRCPC   (Site not responding. Last check: 2007-10-08) Since glucagonoma may arise in the context of a polyfunctional endocrine tumor, assessing serum glucagon, in addition to serum insulin, gastrin, and vasoactive intestinal peptide levels, is important. Necrolytic migratory erythema in a patient with glucagonoma syndrome. Acanthosis with upper epidermal necrolysis from a patient with necrolytic migratory erythema and glucagonoma syndrome. www.emedicine.com /derm/topic168.htm   (2678 words)

eMedicine - Glucagonoma : Article by Luigi Santacroce, MD Glucagonoma very rarely is a member of multiple endocrine neoplasia type 1 (MEN I) syndromes, and, in such cases, it appears as a single lesion and is biologically inactive. In approximately 80% of cases, glucagonoma is a carcinoma, and it is an adenoma in 20% of cases. The main complication of glucagonoma is hepatic metastasis or metastasis of the locoregional lymph nodes. www.emedicine.com /med/topic896.htm   (3859 words)

Cytogenetics of multiple endocrine neoplasia syndrome. II. Chromosome abnormalities in an insulinoma and a glucagonoma ...   (Site not responding. Last check: 2007-10-08) Chromosome abnormalities in an insulinoma and a glucagonoma from two subjects with MEN1.The insulinoma had a modal peak at 84 chromosomes. The glucagonoma had a nearly equal proportion of normal metaphases and metaphases with structural and numerical abnormalities with no consistent trend. Cytogenetic analysis of two pancreatic islet tumors, an insulinoma and a glucagonoma was ascertained in two subjects with multiple endocrine neoplasia type 1 (MEN1). www.pdg.cnb.uam.es /UniPub/iHOP/gp/7216742.html   (145 words)

Echenique-Elizondo M, et al. Glucagonoma and Pseudoglucagonoma Syndrome. JOP. J Pancreas (Online) 2004; 5(4):179-185. ... Context Glucagonoma syndrome may present either associated with a pancreatic neoplasm which secretes glucagon or as a pseudo-glucagonoma associated with other diseases. The follow-up was of 8, 37 and 57 months in the cases of true glucagonoma syndrome. Scintigraphic long-term follow-up of a patient with metastatic glucagonoma. www.joplink.net /prev/200407/04_c.html   (685 words)

Statistics by Country for Glucagonoma - WrongDiagnosis.com About these extrapolations of prevalence and incidence statistics for Glucagonoma: These statistics are calculated extrapolations of various prevalence or incidence rates against the populations of a particular country or region. As such, these extrapolations may be highly inaccurate (especially for developing or third-world countries) and only give a general indication (or even a meaningless indication) as to the actual prevalence or incidence of Glucagonoma in that region. The term 'incidence' of Glucagonoma means the annual diagnosis rate, or the number of new cases of Glucagonoma diagnosed each year (i.e. www.wrongdiagnosis.com /g/glucagonoma/stats-country.htm   (393 words)

Glucagonoma - TheBestLinks.com - Amino acid, Abdomen, Glucose, Hormone, ...   (Site not responding. Last check: 2007-10-08) Glucagonoma - TheBestLinks.com - Amino acid, Abdomen, Glucose, Hormone,... Glucagonoma, Amino acid, Abdomen, Glucose, Hormone, Hemoglobin, Histology... Somatostatin analogue in treatment of coexisting glucagonoma and pancreatic pseudocyst: dissociation of responses (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieveanddb=PubMedanddopt=Abstractandlist_uids=90371458) www.thebestlinks.com /Glucagonoma.html   (503 words)

Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma -- Valverde et al. 42 (5): 804 ... Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma -- Valverde et al. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma glucagonoma and a total plasma glucagon level of 2600 pg/ml, revealed the jcem.endojournals.org /cgi/content/abstract/42/5/804   (210 words)

Metastatic glucagonoma de-differentiated to an insulinoma: response to embolization Metastatic glucagonoma de-differentiated to an insulinoma: response to embolization CTscan revealed a mass in the pancreatic tail and hepatic metastases consistent with malignant glucagonoma. In conclusion, this lady has a metastatic glucagonoma that has de-differentiated to an insulinoma, whose symptoms have been successfully alleviated by hepatic embolization of the liver metastases. www.endocrine-abstracts.org /ea/0007/ea0007p112.htm   (320 words)

Misdiagnosis of Glucagonoma - CureResearch.com About misdiagnosis: When checking for a misdiagnosis of Glucagonoma or confirming a diagnosis of Glucagonoma, it is useful to consider what other medical conditions might be possible misdiagnoses or other alternative conditions relevant to diagnosis. These alternate diagnoses of Glucagonoma may already have been considered by your doctor or may need to be considered as possible alternative diagnoses or candidates for misdiagnosis of Glucagonoma. Glucagonoma misdiagnosed as another condition: Sometimes a physician may misdiagnose Glucagonoma incorrectly as another condition when the correct diagnosis is Glucagonoma. www.cureresearch.com /g/glucagonoma/misdiag.htm   (386 words)

Causes of Glucagonoma - WrongDiagnosis.com Glucagonoma as a complication: Other conditions that might have Glucagonoma as a complication might be potential underlying causes of Glucagonoma. What causes Glucagonoma?: Related information for Glucagonoma causes, as with all medical conditions, there may be many causal factors. Further relevant information on causes of Glucagonoma may be found in the risk factors for Glucagonoma, medications that may cause Glucagonoma, contagiousness for Glucagonoma, genetics of Glucagonoma, and underlying causes of Glucagonoma. www.wrongdiagnosis.com /g/glucagonoma/causes.htm   (173 words)

Glucagonoma syndrome presenting as psoriasis -- Beattie et al. 95 (12): 834 -- QJM Glucagonoma syndrome presenting as psoriasis -- Beattie et al. The cutaneous eruption of glucagonoma is described as a distinct psoriasis and subsequently was diagnosed as having glucagonoma qjmed.oxfordjournals.org /cgi/content/full/95/12/834   (543 words)

National Cancer Institute - Islet Cell Carcinoma (Pancreatic) Treatment Glucagonoma is the third most common endocrine-secreting islet cell tumor and 70% of glucagonomas are malignant. Somatostatin analogue therapy (SMS 201-995).[2] Necrotizing erythema of glucagonoma is relieved in 24 hours with somatostatin analogue, with nearly complete disappearance within 1 week. Somatostatin analogue therapy (SMS 201-995) for WDHA syndrome and pancreatic polypeptide.[2] Necrotizing erythema of glucagonoma is relieved in 24 hours with somatostatin analogue, with nearly complete disappearance within 1 week. www.nci.nih.gov /cancertopics/pdq/treatment/isletcell/healthprofessional/allpages/print   (2463 words)

Glucagonoma - Diabetes glucagonoma mellitus also frequently results from the insulin and glucagon imbalance that occurs in glucagonoma. A disease is any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The broader body of knowledge about diseases and their treatments is medicine. www.medicalgeo.com /Med-Diseases-F---G/Glucagonoma.html   (522 words)

Ghrelin Expression in Islet Cell Tumors: Augmented Expression of Ghrelin in a Case of Glucagonoma with Multiple ... Lane 1, Patient 1 glucagonoma; lane 2, patient 1 glucagonoma RT (-); lane 3, patient 2 glucagonoma; lane 4, patient 2 glucagonoma RT (-); lane 5, patient 1 insulinoma; lane 6, patient 1 insulinoma RT (-); lane 7, patient 2 insulinoma; lane 8, patient 2 insulinoma RT (-). Immunohistochemistry of ghrelin in patient 2 with glucagonoma. A, Ghrelin-like immunoreactivity was observed in nearly all tumor cells in patient 1 glucagonoma. jcem.endojournals.org /cgi/content/full/87/11/4885   (2754 words)

Metastatic glucagonoma transforming to an insulinoma We present the case of a 75 year-old man diagnosed to have a glucagonoma in 1995. Hypoglycaemia responded partially to octreotide and currently patient's hypoglycaemic symptoms are well controlled on monthly long acting octreotide although his overall condition is deteriorating due to increasing tumour load. This patient presents an unusual scenario where a neuroendocrine tumour initially presented as a glucagonoma and subsequently the predominant hormone secretion changed to that of insulin. www.endocrine-abstracts.org /ea/0007/ea0007p156.htm   (252 words)

The glucagonoma syndrome and necrolytic migratory erythema: a clinical review -- van Beek et al. 151 (5): 531 -- ... The glucagonoma syndrome and necrolytic migratory erythema: a clinical review -- van Beek et al. The glucagonoma syndrome is a rare disease in which a typical skin disorder, necrolytic migratory erythema, is often one of the first presenting symptoms. In addition, glucagonomas may produce various other products, like pancreatic polypeptide, that add to the catabolic effects of glucagon. www.eje-online.org /cgi/content/abstract/151/5/531   (244 words)

IngentaConnect Brittle nails and dyspareunia as first clues to recurrences of ma... Glucagonoma syndrome is a paraneoplastic syndrome in which the occurrence and resolution of the characteristic necrolytic migratory erythema lesions parallel the course of the underlying glucagonoma. We describe a case of glucagonoma syndrome in which recurrent brittle nails and dyspareunia gave the patient the first clues of the recurrence of glucagonoma. It is possible that the significance of onychoschizia and dyspareunia has been overlooked in glucagonoma syndrome because patients might not report these problems to their doctors. www.ingentaconnect.com /content/bsc/bjd/2002/00000146/00000006/art04673   (211 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.